REVLIMID-Treated Patients with Deletion-5q MDS Who Achieve Transfusion-Independence of At Least 26 Weeks and AML-Free Survival Associated with Cytogenetic Response

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation CELG today announced that results from a retrospective analysis of patients with International Prognostic Scoring System (IPSS) Low- or Intermediate (Int)-1-risk myelodysplastic syndromes (MDS) with del(5q) treated with REVLIMID® (lenalidomide) were presented at the American Society of Hematology annual meeting in New Orleans, La. In the analysis, 286 patients from the MDS-003 and MDS-004 studies received lenalidomide from the study start. Of the total, 181 were evaluable for both cytogenic response (CyR) and red-blood cell transfusion independence (RBC-TI) of at least 26 weeks, (88 patients from MDS-003 and 93 patients from MDS-004). See full press release